Published in final edited form as:

J Proteome Res. 2019 March 01; 18(3): 1380–1391. doi:10.1021/acs.jproteome.9b00004.

Proteomic Atlas of the Human Brain in Alzheimer's Disease

Justin McKetney¹, Rosie Runde^{2,3}, Alexander S Hebert⁴, Shahriar Salamat^{2,3}, Subhojit Roy^{2,3}, and Joshua J. Coon^{1,4,5,6,*}

¹Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI 53706

²Department of Pathology and Laboratory Medicine, University of Wisconsin–Madison.

³Department of Neuroscience, University of Wisconsin–Madison, 1111 Highland Avenue, Madison, Wisconsin 53705

⁴Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI 53706

⁵Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706

⁶Morgridge Institute for Research, Madison, WI 53706

Abstract

The brain represents one of the most divergent and critical organs in the human body. Yet, it can be afflicted by a variety of neurodegenerative diseases specifically linked to aging, about which we lack a full biomolecular understanding of onset and progression, such as Alzheimer's Disease (AD). Here we provide a proteomic resource comprising nine anatomically distinct sections from three aged individuals, across a spectrum of disease progression, categorized by quantity of neurofibrillary tangles. Using state-of-the-art mass spectrometry, we identify a core brain proteome that exhibits only small variance in expression, accompanied by a group of proteins that are highly differentially expressed in individual sections and broader regions. AD affected tissue exhibited slightly elevated levels of tau protein with similar relative expression to factors associated with the AD pathology. Substantial differences were identified between previous proteomic studies of mature adult brains and our aged cohort. Our findings suggest considerable value in examining specifically the brain proteome of aged human populations from a multiregional perspective. This resource can serve as a guide, as well as a point of reference for how specific regions of the brain are affected by aging and neurodegeneration.

For TOC only

*Corresponding author: jcoon@chem.wisc.edu.

Keywords

Alzheimer's disease; neurodegeneration; brain tissue; quantitative proteomics; human proteomics; mass spectrometry; multiregional; aged brain; cortical samples; limbic samples

Introduction

As evinced by its highly variable protein expression profile, the brain embodies one of the most divergent and specialized organs in the body [1, 2]. A recent study comparing 13 human tissues found that after the testes, the brain had the second highest occurrence of tissue-enriched genes [3]. And due to diverse cell types and functions, expression levels vary between different areas of the mammalian brain, creating a heterogeneous environment of protein expression in a single organ [4, 5]. Given its unique role, it is not surprising that the brain is specifically susceptible to a host of diseases associated with aging, including Alzheimer's disease (AD) and other neurodegenerative disorders. AD makes up more than half of dementias with more than 40 million people suffering from AD globally in 2015 [6]. In 2017, an American developed AD every 66 seconds – a rate that is projected to accelerate considerably in the next decades due to increasing life spans and an aging population [7]. Although the pathology originates in the transentorhinal region and spreads through the hippocampal formation and hippocampus proper on to the neocortex, there is little known about the sequential effects on cellular function in different regions of the brain [8, 9].

The pathological decline associated with AD is driven by protein, specifically the aggregation of amyloid and tau protein into neritic plaques and neurofibrillary tangles, respectively. Current hypotheses suggest that the abnormal processing of amyloid precursor leads to the development of plaques, while abnormal phosphorylation of tau can promote aggregation [10, 11]. Other proteins play roles in the associated increase in neuronal damage; both as drivers of aggregation [12] and aggravating damage caused by the aggregates [13]. Cellular protein production and function is deeply intertwined with the pathological effect of AD decline within the cell and in the extracellular space. We conclude that to improve our understanding of neurodegeneration and AD progression, a comprehensive view of brain protein expression is required.

Several large-scale projects have examined protein expression in the mammalian brain. Mouse models can be leveraged to study neurodegenerative diseases such as Parkinson's [14] and Alzheimer's [15, 16]. However, animal models are often incomplete and fail to encompass the full variety of protein changes that occur in the human brain with pathological decline and aging, considering substantial differences life span [17]. As RNA-based technologies have improved, several projects such as PsychEncode [18], BrainSpan [19] and the Allen Brain Atlas [20] have emerged that quantified transcripts as a measure of protein expression directly from post-mortem human tissue. Transcriptomic studies have also been performed that specifically target Alzheimer's disease [21]. Despite the impressive scope of these studies, several analyses have implicated that protein expression can be regulated at the translational level with different half-lives between mRNA transcripts and proteins [22, 23]. This causes a discrepancy in predicting certain protein abundances from transcripts, a phenomenon that has been observed in the brain previously [17, 24]. Recently, a multi-regional analysis of protein expression at a variety of developmental time points was performed, including individuals with ages spanning from less than one to forty years old [17]. These time points precede the onset of neurodegeneration in the human brain, and though proteomic experiments have been performed that specifically target neurodegeneration with age, they have quantified levels of hundreds of proteins rather than the thousands that are present [25, 26] or have examined only a small number of brain regions [24, 27]. Many of these studies have focused on the parietal and frontal cortex [24, 27] and the hippocampal area [28–30] despite identification of differentially expressed proteins in AD in a variety of regions of the brain, even those that are often tangle-free [26]. We posit that a more comprehensive atlas of protein expression in the aged human brain would accelerate our understanding of neurodegeneration and dementia.

Here we present a resource cataloging the expression of thousands of proteins in nine distinct sections of the aged human brain. This protein compendium is based on nine sections from three individual brains (Figure 1). The sections include: Amygdala (AMY), Caudate Nucleus (CNC), Cerebellum (CBM), Entorhinal Cortex (ECX), Inferior Parietal Lobule (IPL), Middle Frontal Gyrus (MFG), Superior Temporal Gyrus (STG), Thalamus (THA), and Visual Cortex (VCX). The three individuals were chosen to cover a spectrum of AD decline, as determined by Braak staging [31]. Braak staging categorizes AD progression based on the spread of neurofibrillary tangles from tau on a scale of 1–6. The “no tangle” brain (0) contained no observable tangles upon dissection and is not afflicted with Alzheimer's disease. The “intermediate tangle” brain (+) was categorized as stage III with tangles identified primarily in the entorhinal region [31]. The “severe tangle” brain (++) falls into the stage VI category with tau aggregates widespread and likely resulting in isocortical destruction [31]. Utilizing state-of-the-art peptide fractionation, liquid chromatography, and tandem mass spectrometry we have collected a high-resolution human brain protein compendium featuring nearly 10,000 unique proteins.

Experimental Methods

Tissue Extraction.

Individual brains were extracted and rapidly flash frozen with a maximum post-mortem interval of five hours for the atlas and fifteen hours for the secondary cohort. (Supplemental Table 1). Brains were stored in -80°C freezers, taken out and given to the clinical neuropathologist to collect precise brain samples, which averaged about 1g. After collection they were immediately put on dry ice and sent to the proteomics lab.

Tissue Staining.

Slices were taken from anterior hippocampal region and sectioned using a microtome. Sections were warmed to incubation temperature before being stained with α -phosphorylated tau protein antibody for 15 mins. Tissue sections were then stained with hematoxylin before being imaged.

Extraction and Digestion.

Each tissue sample was suspended in 1.2 ml lysis buffer (6M Guanadine HCl, 100mM Tris pH 8) before being probe sonicated (Misonix XL-2000) to lyse the cells. After sonication a protein BCA assay (Thermo Scientific) was performed to determine protein concentrations of the lysate. Sample lysates ranged in concentration from approximately 6–13 mg/ml. 500ug of protein was aliquoted from each sample lysate. Each aliquot was brought up to 90% methanol before being centrifuged at 14,000 g for 5 min. Supernate was disposed and the precipitate was resuspended in 240ul of reducing and alkylating buffer (8M urea, 10mM TCEP, 40mM CAA, 100mM Tris pH 8). The sample solution was then diluted to 25% concentration with 100mM Tris, pH 8. Trypsin was added to the protein lysate sample at a ratio of 50:1 w/v and digested overnight. Digested samples were desalted using Strata-X Polymeric Reverse Phase column (Phenomenex). Samples were then dried in SpeedVac Concentrator.

Fractionation

Dried samples were resuspended in 0.2% formic acid before fractionation using an HPLC (Agilent, Infinity 2000) with a C18 reverse-phase column (Waters, XBridge Peptide BEH, particle size 3.5um). Mobile phase buffer A was a fresh-made mixture of 10mM ammonium acetate, pH 10, while mobile phase buffer B was composed of 10mM ammonium acetate, 80% methanol, pH 10. Each sample was separated into 32 fractions. Fractions were collected directly in a round-bottom 96-well plates, allowing three samples to be contained in each plate. Fractions were concatenated by combining fractions 1–8 with 18–25 and combining fractions 9–17 with 26–32, to yield 16 fractions. In the interest of time fraction number was again reduced to 12 by pooling 15 & 16, 13 & 14, 1 & 2, and 3 & 4. Plates were dried down in the SpeedVac Concentrator. Samples were resuspended in 0.2% formic acid for instrument injection

LC-MS/MS

Online reverse-phase columns were prepared in house. A laser puller was used to generate tips on ~35cm long silica columns with an inner diameter of 75µm and an outer diameter of 360µm. Columns were filled with 1.7µm, 130 Å pore size, Bridged Ethylene Hybrid C18 particles. Column was heated and maintained at a temperature of 50°C and connected to instrument by an embedded emitter. A Waters UHPLC was used for online chromatography with mobile phase buffer A consisting of 0.2% formic acid and mobile phase buffer B consisting of 0.2% formic acid with 70% acetonitrile. Fractionated Samples were loaded onto the column for 12 min at a flow rate of 0.35 µl/minute. Mobile phase B increased to 4% in the first min then increased on a gradient to 55% B at 75 minutes. The method increased percent B to 100% by 76 minutes. Method ended with 3 min wash at 100% B and 10 min wash at 0% B.

Single shot samples were analyzed using 120 min LC method where Samples were loaded onto the column for 7 min at a flow rate of 0.33 µl/minute. Mobile phase B increased to 7% in the first 6 min then increased on a gradient to 50% B at 104 minutes. The method increased percent B to 100% by 105 minutes. Method ended with 5 min wash at 100% B and 10 min wash at 0% B.

Eluting peptide fragments were ionized by electrospray ionization and analyzed on a Thermo Orbitrap Fusion Lumos. Survey scans of precursors were taken from 300 to 1350 m/z at 240,000 resolution while using Advanced Precursor Determination. Tandem MS was performed using an isolation window of 0.7 Th with a 25ppm mass tolerance and a dynamic exclusion time of 20s. Selected precursors were fragmented using a normalized collision energy level of 30. MS² ion count target was set at 2×10^4 ions with a maximum injection time of 18 milliseconds. Scans were taken at the rapid speed setting and only peptides with a charge state of +2 or greater were selected for fragmentation.

Data Searching & Analysis

All raw files from the fractionated samples were searched together in the software MaxQuant(version 1.5.2.8) [32] with each sample input as an experiment made up of 12 fractions. Spectra were searched using fast LFQ against a full human proteome with isoforms downloaded from Uniprot (June 14, 2017). Carbamidomethyl was set as a fixed modification. Matching between runs was used with a retention time window of 0.7 mins. Searches were performed using a protein FDR of 1%, a minimum peptide length of 7, and 0.5 Da MS² match tolerance. Protein data was then extracted from the "ProteinGroups.txt" file of the Maxquant output after decoy, contaminants, and reverse sequences were removed. All single shot samples were searched together using the same parameters, with the only difference being the use of a more recent human proteome from Uniprot (November 29, 2018). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [33] partner repository(<http://www.ebi.ac.uk/pride/archive/>) with the dataset identifier PXD010603.

Data imputation and hierarchical clustering were performed using an in-house data development tool(coonlabdatadev.com). Imputation was performed for proteins observed in

at least 50% of the samples from each section, by replacing missing values with values selected from the lowest 3% of the distribution of log transformed intensities. Boxplots were generated using R and Boxplotr [34]. Pearson correlations were performed in R. To ensure we were not altering trends with imputation the Pearson analyses was also performed using only proteins observed in all samples and the results were indistinguishable from the confidently imputed dataset. Gene ontology enrichment was performed using the National Cancer Institute Database for Annotation, Visualization and Integrated Discovery (DAVID).

Results

Overall Protein Statistics

Tissue sections were lysed by probe sonication and proteins were extracted, denatured, and digested with trypsin [35]. Digested peptides were then fractionated using high-pH reverse-phase liquid chromatography, before being pooled and injected onto our liquid chromatography setup online with the Fusion Lumos Mass Spectrometer[36, 37]. This procedure was performed on all nine sections: Amygdala (AMY), Caudate Nucleus (CNC), Cerebellum (CBM), Entorhinal Cortex (ECX), Inferior Parietal Lobule (IPL), Middle Frontal Gyrus (MFG), Superior Temporal Gyrus (STG), Thalamus (THA), and Visual Cortex (VCX). Overall, we identified 9,735 proteins in at least one sample with 5,098 proteins identified in all 26 samples (Supplemental Table 2). [38, 39]. On average, 7,387 proteins were quantified in each sample, with the fewest observed in the caudate nucleus and the most observed in the middle frontal gyrus. This equates to greater than 50% of the gene products found to be expressed in the brain by the Human Protein Atlas (14518 transcripts) and ~60% of proteins identified in the deepest proteomic study of the brain to date (11,840 proteins) [27, 40](Table 1). 6,256 proteins were quantified in at least 50% of samples from each anatomical region, meaning at least one CBM sample and two or more samples from all other regions (Supplemental Table 3). 7,706 proteins were identified in all samples from at least one section of the brain, reflecting a consistency between individuals' expression within regions. Figure 2a shows the distribution of proteins between the sections. More than 70% of proteins were identified in all nine sections, with 12% identified in only one section and ~18% identified in 2–8 sections. The 9,735 proteins identified overall correspond to 129,050 identified unique peptides. On average, proteins were identified by greater than 11 peptides comprising greater than 23% sequence coverage. Only 211 proteins were identified by a single peptide, while the largest number of peptides attributed to a single protein was neuroblast differentiation-associated protein AHNAK with 358 peptides.

Sectional Similarity

With the global map of protein expression in hand we first performed a hierarchical clustering of the 6,250 proteins that were identified in at least half of the samples from each section. Proteins were clustered by Pearson correlation while tissue samples were clustered using Spearman correlation. We observed that the two CBM (cerebellum) samples exhibit a strong divergence from the all other sections (Figure 2b). A similar result was reflected in our principal component analysis (Supplemental Figure 1) with both CBM samples greatly separated from all others by component 1 which encompasses 23.4% of variance. The heat

map in Figure 2b shows that this difference is driven heavily by two protein clusters: cluster 43 and cluster 28 (Figure 2b).

When Gene Ontology (GO) enrichment was performed on cluster 43 the most significant associated biological processes were related to “transcription” and “mRNA processing”. Cluster 43 also included an abundance of proteins related to chromatin maintenance and nucleosome assembly, all of which are processes associated with the cell body and the nucleus, an observation corroborated by previous analysis of the brain proteome [17]. This data suggests that the cerebellum (CBM) samples may be converging due to an increased nuclei density relative to other sections of the brain. Enrichment analysis on cluster 28 shows decreased expression of proteins associated with the membrane and the process of “synaptic transmission”. These expression differences support previous findings [41] suggesting the cerebellum is defined by increased cell density as well as decreased participation in specialized signaling relative to the rest of the brain.

Protein levels also exhibited similarity between regions found in the same area more broadly, with the highest order groupings in our clustering separating the sections in the limbic system and those contained in the cerebral cortex (Figure 2b). One group contains all limbic sections including the THA, CNC, AMY as well as one ECX sample, while the other group includes all the cerebral cortex sections, which includes the MFG, IPL, STG, VCX, as well as the CBM samples. These groupings fall generally into interior and exterior of the brain. (Figure 2b & Figure 1).

To examine similarities in protein expression we performed a pairwise Pearson Correlation between all samples. We observed the strongest positive correlations between the same sections in different individuals, even more so in relatively isolated regions such as the thalamus (Figure 2c). A weaker positive correlation was shown among sections located in the same basic region with THA, CNC, and AMY showing some positive correlation. This same weak positive correlation is seen among the sections of the cerebral cortex in the relationships of MFG, IPL and STG in the upper right of Figure 2c. A corresponding broadly negative correlation is seen in the center of Figure 2c when comparing the protein profiles of more distant sections of the brain across these different broad regions.

Differentially expressed proteins

We examined more closely three sections that had particularly strong correlations: MFG, CNC, and IPL. The samples from each of these sections were averaged for each protein and then expression differences were compared (Supplemental Table 4). The protein profile of the frontal gyrus and the caudate nucleus show an anti-correlation overall (Pearson's $r = -0.42$) that becomes quite strong (Pearson's $r = -0.81$) if we focus on proteins with greater variation ($>20\%$ change) and slightly greater significance ($p\text{-value} < 0.05$) (Figure 3a). The opposite is true of the relationship between MFG and IPL, adjacent lobes of the cerebral cortex, which starts with a positive correlation (Pearson's $r = 0.52$) that becomes stronger when selecting for more variable and significant proteins (Pearson's $r = 0.94$). If this grouping is reversed and only proteins with minimal variations ($<20\%$ expression change) and significance ($p > 0.05$) are used the correlation between MFG and CNC is largely eliminated (Pearson's $r = -0.13$). The gene products within this low correlation group show

gene ontology enrichment for “cell-cell adhesion” and “vesicle transport”, biological processes ubiquitous to the brain. This leads to the hypothesis that there may be a core brain proteome that exhibits little variation throughout the different anatomical features, as well as a group of variably expressed proteins that account for regional deviation in the proteome.

1411 proteins showing significant differential expression (Bonferroni adj. $P < 0.05$) in at least one section and were grouped into 15 clusters using the Ward’s method (Figure 3b & c, Supplemental Figure 2 & Supplemental Table 4). As was observed in other analyses the sectional differences were dominated by the cerebellum, leading to mRNA processing proteins and those related to nuclear function driving many of the larger clusters such as Cluster 13 shown in Figure 3b. Cluster 2 includes proteins with low expression in the cerebral cortex regions (MFG, IPL and STG) and elevated expression in the caudate nucleus and amygdala with the highest expression in the thalamus (Figure 3c). This group shows GO enrichment for proteins associated with the oxidation-reduction process with 14 proteins included in that grouping and many others involved in other aspects of metabolism. It has been shown previously that the functionality of antioxidants and therefore mediation of oxidative stress can be associated with AD[42–44] and that these effects can vary significantly by region with age and potentially neurodegeneration[45].

A collection of differentially expressed gene products between healthy, aged brains and those with Alzheimer’s disease was assembled using a wide range of previous literature[24–29, 46, 47]. Of the more than 1400 proteins with altered expression associated with pathological decline, 326 of them were identified in our region-specific expression group, with all regions, but the IPL containing at least one of these gene products (Figure 4a). This suggests that many of the same proteins that are defining the expression profiles of a region, whether due to function or cell population, are also significantly connected to the pathology of AD.

We performed a series of single shot experiments focusing on two contrasting regions of the brain: the entorhinal cortex and the neocortex. We prepared and analyzed tissue from 7 additional individuals, 3 healthy age-matched controls, and 4 AD afflicted individuals, in parallel with our corresponding original samples, MFG, IPL, STG (neocortex) and ECX (entorhinal cortex). The 5 AD individuals included fresh neocortex and entorhinal cortex tissue from case 383, the severe tangle brain used in the atlas. We identified 5520 proteins overall but focused our analysis on the 3244 proteins identified in all experiments. We grouped these data into either neocortex or entorhinal cortex and diseased or healthy tissue and performed a two-way ANOVA with the two variables “region” and “disease”. We found 594 proteins that were significantly regulated after multiple hypothesis correction (Benjamini-Hochberg, 5% FDR) for one or both variables (Figure 4b & c). 227 out of the 588 proteins found to be regionally expressed in this expanded study were also identified in the previous region-specific group of the atlas. 9 proteins out of 17 disease-associated proteins from our expanded study were also identified from the Alzheimer’s literature. 13 significantly regulated proteins from our expanded study show a 2-fold larger shift in abundance in one region than the other with the addition of AD (Figure 4b). These proteins are associated with the formation of the extracellular matrix (EPB41L1, HAPLN4, TENA), vesicle signaling (CAYP1, SYT2,) and the immune system (S100B, ICAM1, CD44,,

ANXA1) all of which are cell functions affected in the development of Alzheimer's disease [48–51] and help define the differences between brain regions due to architecture, cell populations and function[52–55]. All of these proteins were flagged by region rather than disease suggesting they would not have been identified if all regions had been treated as a single Alzheimer's disease group. When comparing AD and healthy controls of the two regions independently we found no overlap in the 30 proteins most significantly associated with disease (Supplemental Figure 3) further supporting different pathological effects on these two regions of the brain.

Expression of Microtubule-Associated Protein Tau

The individual subjects in our study were categorized using Braak staging, which grades pathological progression based on spread and density of neurofibrillary tangles. Upon dissection, brain tissue was stained for aggregates of microtubule associated protein tau (MAPT) using an α -phosphorylated tau antibody (Figure 5a). Tau expression was compared between the “no tangle” brain and both the intermediate and severe tangle brains (Figure 5b). The severe tangle brain exhibited greater levels of tau protein in all but one section, VCX. The intermediate tangle brain showed elevated tau protein in more than half of the sections with AMY exhibiting more than double the levels found in the control brain. The tau protein ratios of the severe and intermediate AMY represent p-values of 0.063 and 0.080, respectively, based on the abundance ratios of all proteins present in the three sample from that region. The samples in our expanded study showed on average slightly elevated tau protein levels between the AD positive samples and the controls.

A subgroup of proteins was identified that had highly similar expression profiles to those of microtubule associated protein tau across these samples (Figure 5c). Generally, these proteins are related to cell growth, development and the metabolism required for division. All these proteins continued to show an association with MAPT in our expanded study except for RAPGEF6 and ACAT2, although there was a positive correlation between MAPT in and ACAT1 (Supplemental Figure 4). Several of the associated gene products, such as MAP1A and MAPRE2, are involved directly in microtubule formation and stability, linking to the healthy function of MAPT. MAP1A works in a compensatory fashion in microtubule assembly in MAPT knockout animals [56] and so may be similarly expressed to replace aggregated tau. Many of the non-structural proteins have been linked to AD directly or are known to be expressed in the brain. Mitochondrial carrier homolog (MTCH1), has a quantitative trait locus correlation with cases of AD [57]. Tenascin-R (TNR) contributes to the alteration of the extracellular matrix during the development of the plaque and tangle pathology [49]. Both Acetyl-CoA acetyltransferase (ACAT2) and Mitogen activated protein kinase 1 (MAPK1) are candidate therapeutic targets for AD[58, 59]. ACAT-inhibitors have slowed the development of amyloid plaques while MAPK1-inhibition is hypothesized to reduce hyperphosphorylation of the tau proteins which can lead to aggregation [59]. While fibroblast growth factor 12 (FGF12) and metallo-beta-lactamase domain-containing protein (MBLAC) are expressed in the human brain, they have not been linked to either the structural or pathological function of tau protein [60–62]. Spectrin beta chain (SPBT2) interacts with alpha-synuclein, one of the hallmarks of another neurodegenerative disease, Parkinson's[63].

Comparison to other Human Brain Proteome Datasets

Recently a study examined protein expression in seven sections of the brain at developmental time points ranging from less than one year to 40 years old [17]. This experiment relied on a peptide library for each section pooled from the five “adult” samples (23–40 years old). When this protein library was compared to our 26 samples, 3682 proteins were quantified in both studies. Comparing the mean-normalized expression, similar profiles were observed between many of the shared and proximal sections in the two experiments (Figure 6a) with a positive correlation between all of our samples in the cerebellum, visual cortex, amygdala and thalamus and the two healthier samples in the frontal lobe and caudate nucleus, two regions known to be affected in AD.

Raw data files for shared sections that were believed to be strongly affected by aging were searched together using the software MaxQuant. These included VCX, AMY, MFG, and CNC samples. The “proteome ruler” calculation in Perseus was then used to estimate copy number per cell [64]. All samples fell within the range of 0.9–3% for the proportion of total signal attributed to histones. Although this is slightly lower than the typical proportion of 2–4% [64] it could possibly be attributed to lower cell body density of neuronal tissue. Protein counts were then compared between the older individuals in our study and the “adult” age group from the previous study, which included five individuals aged 23–40 years. The protein counts were analyzed using a paired tail t-test with correction for multiple hypotheses using the Benjamini-Hochberg method with a false discovery rate (FDR) of 5%. Overall, 621 proteins increased in the older individuals while only 37 were found to decrease with age. The frontal lobe contained the most of these differentially expressed proteins with 478 proteins increasing with age (Figure 6b & c). The proteins identified here do not seem to have a unifying process or function but many of them are localized to similar cellular compartments, namely the “membrane” and the “extracellular exosome”. The disparity between proteins increasing with age as compared to those decreasing should not be particularly surprising given the slow turnover of proteins in the brain [65]. The proteins that show correlation with age exhibit very little overlap between regions, with only THA and MFG sharing substantial number of proteins. This furthers our hypothesis that regional proteomic differences play a role in the effects of aging and neurodegeneration.

Focusing on the large group of proteins identified in the frontal lobe, we performed this same analysis with the inclusion of our expanded panel of neocortex samples from our single-shot analysis. Protein counts were compared between young, healthy-aged, and diseased-aged neocortex samples using a one-way ANOVA. Of the 478 proteins with abundance changes in our original analysis of the frontal lobe, 399 of them were found to be significant with an expanded sample size. Unsurprisingly, a majority of proteins (301) were found to be significant when comparing young to both healthy aged and diseased samples, while 57 proteins were significant in the young to healthy-aged comparison only and 41 in the young to diseased comparison only.

Discussion

We anticipate that this resource will prove highly informative and useful to both the human proteomics and neuroscience community. Overall, we quantified 9,748 proteins from

129,680 peptides, with an average of 11 peptides per protein. This is, to our knowledge the largest dataset of multiregional proteomics focused on aged subjects or Alzheimer's disease [25]. The number of sections and depth acquired in this proteomic analysis richly illustrates the dynamic nature of the human brain proteome.

Examining the expression of the 6,258 proteins we observed sectional similarity of expression across individuals and disease states. This proteomic similarity reflects a distinct expression pattern that may be related to cell populations or functionality within these anatomical features. More importantly for this resource, it begins to validate comparison of sectional proteomes from different individuals. As we widen our analysis, larger-scale trends appear, separating the major regions of the brain by protein expression, with the limbic system, the cerebral cortex and the cerebellum all showing distinct profiles. A large proportion of proteins, even those involved in neuronal function are expressed with minimal variation across samples. Differentially expressed proteins can be used to glean insight into cell populations and cellular function as we saw in the cerebellum sections in this study and has been seen in mouse models [4, 14].

There is no reason to believe that this regional difference in expression is not reflected in the effects of AD and in fact, many of the proteins identified here as regionally expressed have also been identified in association with Alzheimer's disease in previous large-scale proteomics studies. This supports the hypothesis that different regions of the brain experience varying effects with pathological decline in terms of the effected proteins, magnitude and direction of changes in abundance. Upon analysis of a larger set of samples with a limited number of regions, we identified a substantial number of proteins that were significantly different due to both disease and region, reflecting this theory experimentally. In addition, several of the regional differentially expressed proteins showed much larger fold changes with disease in one region than the other indicating a variation in impact of AD. Additional multiregional analysis is required to identify the possible variety of effects Alzheimer's on the different areas of the brain.

Possibly reflecting this diaspora of regional AD effects our label-free quantitation method detected elevated levels of tau protein in samples from the intermediate and severe tangle individuals relative to the control for a majority of sections. Fluctuating in parallel with tau were several other gene products that play a role in formation of cytoarchitecture by way of microtubules and have been linked to the progression of the AD pathology. In addition, we identified several correlating proteins that are expressed in the brain but have no previous link to tauopathies or healthy function. These proteins could represent leads indicative of the changes in cellular function that occur during Alzheimer's decline or more general dementia. Investigating covariation with tau is simply the most obvious and accessible lead to pursue, but others have already developed large libraries of genes and proteins associated with AD, any of which could be used as a focal point to survey this data with an eye toward regional expression of disease-associated proteins.

We observe a strong positive correlation between the global protein expression of regions examined here and the expression in similar regions from previous analyses. In addition, we identified a small group of proteins that exhibit significant difference in abundance between

these two studies, suggesting a possible connection to the process of aging or neurodegeneration. Some of these proteins were identified as being variable by age in this previous study [17]. These proteins had largely positive correlations to age, with older individual brains exhibiting higher normalized counts. These age-correlated proteins also exhibited a regional association, with most showing differences only in a single region. When we performed an expanded analysis on the proteins identified within the frontal lobe, we found that most were associated with aging, with a small subset connected specifically to disease. Whether these trends in other regions are related to brain maturity or neurodegeneration would require an expanded study, but our analysis suggests that a non-insignificant number of these expression changes are linked to specifically to disease.

This resource is not intended to be the final authority but rather the next step in building a foundational atlas of protein expression in the aged brain. As proteomic technologies improve, the depth, coverage and speed of collection for these proteomes will increase as well. We believe that this dataset adds regional nuance and breadth to several excellent resources already in existence, and that multiregional analysis can help fill gaps in our understanding of the progression of aging and neurodegeneration. This analysis and other multiregional studies support the concept of the variable effects of both age and neurodegeneration on the different regions of the human brain. This atlas of the brain likely reflects many of the shifts that this complex organ undergoes during these processes. An expanded study is likely required to fully disentangle those factors from lifestyle and gender. Yet even given those confounding factors here, protein groups surface with notable functional connections and regions show distinct profiles of expression with age and disease. For this reason, we expect this resource to empower the proteomics and neuroscience community in investigating neurodegenerative disease and aging.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge support from the NIH grants P41 GM108538 and R35 GM118110 (to J.J.C). J.M.M. was supported through the Wisconsin Alliance for Minority Participation by NSF grant 0402549.

References

1. Kim MS; Pinto SM; Getnet D; Nirujogi RS; Manda SS; Chaerkady R; Madugundu AK; Kelkar DS; Isserlin R; Jain S; Thomas JK; Muthusamy B; Leal-Rojas P; Kumar P; Sahasrabudhe NA; Balakrishnan L; Advani J; George B; Renuse S; Selvan LD; Patil AH; Nanjappa V; Radhakrishnan A; Prasad S; Subbannayya T; Raju R; Kumar M; Sreenivasamurthy SK; Marimuthu A; Sathe GJ; Chavan S; Datta KK; Subbannayya Y; Sahu A; Yelamanchi SD; Jayaram S; Rajagopalan P; Sharma J; Murthy KR; Syed N; Goel R; Khan AA; Ahmad S; Dey G; Mudgal K; Chatterjee A; Huang TC; Zhong J; Wu X; Shaw PG; Freed D; Zahari MS; Mukherjee KK; Shankar S; Mahadevan A; Lam H; Mitchell CJ; Shankar SK; Satishchandra P; Schroeder JT; Sirdeshmukh R; Maitra A; Leach SD; Drake CG; Halushka MK; Prasad TS; Hruban RH; Kerr CL; Bader GD; Iacobuzio-Donahue CA; Gowda H; Pandey A, A draft map of the human proteome. *Nature*, 2014 509(7502): p. 575–81. [PubMed: 24870542]
2. Wilhelm M; Schlegl J; Hahne H; Gholami AM; Lieberenz M; Savitski MM; Ziegler E; Butzmann L; Gessulat S; Marx H; Mathieson T; Lemeer S; Schnatbaum K; Reimer U; Wenschuh H; Mollenhauer

- M; Slotta-Huspenina J; Boese JH; Bantscheff M; Gerstmair A; Faerber F; Kuster B, Mass-spectrometry-based draft of the human proteome. *Nature*, 2014 509(7502): p. 582–7. [PubMed: 24870543]
3. Uhlen M; Fagerberg L; Hallstrom BM; Lindskog C; Oksvold P; Mardinoglu A; Sivertsson A; Kampf C; Sjostedt E; Asplund A; Olsson I; Edlund K; Lundberg E; Navani S; Szgyarto CA; Odeberg J; Djureinovic D; Takanen JO; Hober S; Alm T; Edqvist PH; Berling H; Tegel H; Mulder J; Rockberg J; Nilsson P; Schwenk JM; Hamsten M; von Feilitzen K; Forsberg M; Persson L; Johansson F; Zwahlen M; von Heijne G; Nielsen J; Ponten F, Proteomics. Tissue-based map of the human proteome. *Science*, 2015 347(6220): p. 1260419. [PubMed: 25613900]
 4. Sharma K; Schmitt S; Bergner CG; Tyanova S; Kannaiyan N; Manrique-Hoyos N; Kongi K; Cantuti L; Hanisch UK; Philips MA; Rossner MJ; Mann M; Simons M, Cell type- and brain region-resolved mouse brain proteome. *Nature neuroscience*, 2015 18(12): p. 1819–31. [PubMed: 26523646]
 5. Lein ES; Hawrylycz MJ; Ao N; Ayres M; Bensinger A; Bernard A; Boe AF; Boguski MS; Brockway KS; Byrnes EJ; Chen L; Chen TM; Chin MC; Chong J; Crook BE; Czaplinska A; Dang CN; Datta S; Dee NR; Desaki AL; Desta T; Diep E; Dolbeare TA; Donelan MJ; Dong HW; Dougherty JG; Duncan BJ; Ebbert AJ; Eichele G; Estin LK; Faber C; Facer BA; Fields R; Fischer SR; Fliss TP; Frensley C; Gates SN; Glattfelder KJ; Halverson KR; Hart MR; Hohmann JG; Howell MP; Jeung DP; Johnson RA; Karr PT; Kaval R; Kidney JM; Knapik RH; Kuan CL; Lake JH; Laramie AR; Larsen KD; Lau C; Lemon TA; Liang AJ; Liu Y; Luong LT; Michaels J; Morgan JJ; Morgan RJ; Mortrud MT; Mosqueda NF; Ng LL; Ng R; Orta GJ; Overly CC; Pak TH; Parry SE; Pathak SD; Pearson OC; Puchalski RB; Riley ZL; Rockett HR; Rowland SA; Royall JJ; Ruiz MJ; Sarno NR; Schaffnit K; Shapovalova NV; Sivisay T; Slaughterbeck CR; Smith SC; Smith KA; Smith BI; Sodt AJ; Stewart NN; Stumpf KR; Sunkin SM; Sutram M; Tam A; Teemer CD; Thaller C; Thompson CL; Varnam LR; Visel A; Whitlock RM; Wornoutka PE; Wolkey CK; Wong VY; Wood M; Yaylaoglu MB; Young RC; Youngstrom BL; Yuan XF; Zhang B; Zwingman TA; Jones AR, Genome-wide atlas of gene expression in the adult mouse brain. *Nature*, 2007 445(7124): p. 168–76. [PubMed: 17151600]
 6. Prince M, World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International, 2015.
 7. Association A, 2017 Alzheimer's disease facts and figures, in Alzheimer's & Dementia. 2017 p. 48.
 8. Braak H; Alafuzoff I; Arzberger T; Kretschmar H; Del Tredici K, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathologica*, 2006 112(4): p. 389–404. [PubMed: 16906426]
 9. Bancher C; Braak H; Fischer P; Jellinger KA, Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. *Neuroscience letters*, 1993 162(1–2): p. 179–82. [PubMed: 8121624]
 10. Grundke-Iqbal I; Iqbal K; Tung YC; Quinlan M; Wisniewski HM; Binder LI, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proceedings of the National Academy of Sciences of the United States of America*, 1986 83(13): p. 4913–7. [PubMed: 3088567]
 11. De Ferrari GV; Inestrosa NC, Wnt signaling function in Alzheimer's disease. *Brain Research Reviews*, 2000 33(1): p. 1–12. [PubMed: 10967351]
 12. Dolan PJ; Johnson GVW, The role of tau kinases in Alzheimer's disease. *Current Opinion in Drug Discovery & Development*, 2010 13(5): p. 595–603. [PubMed: 20812151]
 13. Bonneh-Barkay D; Wiley CA, Brain extracellular matrix in neurodegeneration. *Brain pathology*, 2009 19(4): p. 573–85. [PubMed: 18662234]
 14. Jung SY; Choi JM; Rousseaux MWC; Malovannaya A; Kim JJ; Kutzera J; Wang Y; Huang Y; Zhu WM; Maity S; Zoghbi HY; Qin J, An Anatomically Resolved Mouse Brain Proteome Reveals Parkinson Disease-relevant Pathways. *Molecular & Cellular Proteomics*, 2017 16(4): p. 581–593. [PubMed: 28153913]
 15. Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L, Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science*, 2007 316(5825): p. 750–4. [PubMed: 17478722]
 16. Savas JN; Wang YZ; DeNardo LA; Martinez-Bartolome S; McClatchy DB; Hark TJ; Shanks NF; Cozzolino KA; Lavalley-Adam M; Smukowski SN; Park SK; Kelly JW; Koo EH; Nakagawa T;

Maslah E; Ghosh A; Yates JR, Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology. *Cell Reports*, 2017 21(9): p. 2614–2627. [PubMed: 29186695]

17. Carlyle BC; Kitchen RR; Kanyo JE; Voss EZ; Pletikos M; Sousa AMM; Lam TT; Gerstein MB; Sestan N; Nairn AC, A multiregional proteomic survey of the postnatal human brain. *Nature neuroscience*, 2017 20(12): p. 1787–1795. [PubMed: 29184206]
18. Akbarian S; Liu C; Knowles JA; Vaccarino FM; Farnham PJ; Crawford GE; Jaffe AE; Pinto D; Dracheva S; Geschwind DH; Mill J; Nairn AC; Abyzov A; Pochareddy S; Prabhakar S; Weissman S; Sullivan PF; State MW; Weng Z; Peters MA; White KP; Gerstein MB; Amiri A; Armoskus C; Ashley-Koch AE; Bae T; Beckel-Mitchener A; Berman BP; Coetzee GA; Coppola G; Francoeur N; Fromer M; Gao R; Grennan K; Herstein J; Kavanagh DH; Ivanov NA; Jiang Y; Kitchen RR; Kozlenkov A; Kundakovic M; Li M; Li Z; Liu S; Mangravite LM; Mattei E; Markenscoff-Papadimitriou E; Navarro FC; North N; Omberg L; Panchision D; Parikshak N; Poschmann J; Price AJ; Purcaro M; Reddy TE; Roussos P; Schreiner S; Scuderi S; Sebra R; Shibata M; Shieh AW; Skarica M; Sun W; Swarup V; Thomas A; Tsuji J; van Bakel H; Wang D; Wang Y; Wang K; Werling DM; Willsey AJ; Witt H; Won H; Wong CC; Wray GA; Wu EY; Xu X; Yao L; Senthil G; Lehner T; Sklar P; Sestan N, The PsychENCODE project. *Nature neuroscience*, 2015 18(12): p. 1707–12. [PubMed: 26605881]
19. Kang HJ; Kawasaki YI; Cheng F; Zhu Y; Xu X; Li M; Sousa AM; Pletikos M; Meyer KA; Sedmak G; Guennel T; Shin Y; Johnson MB; Krsnik Z; Mayer S; Fertuzinhos S; Umlauf S; Lisgo SN; Vortmeyer A; Weinberger DR; Mane S; Hyde TM; Huttner A; Reimers M; Kleinman JE; Sestan N, Spatio-temporal transcriptome of the human brain. *Nature*, 2011 478(7370): p. 483–9. [PubMed: 22031440]
20. Hawrylycz MJ; Lein ES; Guillozet-Bongaarts AL; Shen EH; Ng L; Miller JA; van de Lagemaat LN; Smith KA; Ebbert A; Riley ZL; Abajian C; Beckmann CF; Bernard A; Bertagnolli D; Boe AF; Cartagena PM; Chakravarty MM; Chapin M; Chong J; Dalley RA; David Daly B; Dang C; Datta S; Dee N; Dolbeare TA; Faber V; Feng D; Fowler DR; Goldy J; Gregor BW; Haradon Z; Haynor DR; Hohmann JG; Horvath S; Howard RE; Jeromin A; Jochim JM; Kinnunen M; Lau C; Lazarz ET; Lee C; Lemon TA; Li L; Li Y; Morris JA; Overly CC; Parker PD; Parry SE; Reding M; Royall JJ; Schulkin J; Sequeira PA; Slaughterbeck CR; Smith SC; Sotd AJ; Sunkin SM; Swanson BE; Vawter MP; Williams D; Wohnoutka P; Zielke HR; Geschwind DH; Hof PR; Smith SM; Koch C; Grant SGN; Jones AR, An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*, 2012 489(7416): p. 391–399. [PubMed: 22996553]
21. Twine NA; Janitz K; Wilkins MR; Janitz M, Whole Transcriptome Sequencing Reveals Gene Expression and Splicing Differences in Brain Regions Affected by Alzheimer's Disease. *Plos One*, 2011 6(1): e16266. 10.1371/journal.pone.0016266
22. Li JJ; Bickel PJ; Biggin MD, System wide analyses have underestimated protein abundances and the importance of transcription in mammals. *PeerJ*, 2014 2.
23. Schwanhauser B; Busse D; Li N; Dittmar G; Schuchhardt J; Wolf J; Chen W; Selbach M, Global quantification of mammalian gene expression control. *Nature*, 2011 473(7347): p. 337–342. [PubMed: 21593866]
24. Seyfried NT; Dammer EB; Swarup V; Nandakumar D; Duong DM; Yin LM; Deng Q; Nguyen T; Hales CM; Wingo T; Glass J; Gearing M; Thambisetty M; Troncoso JC; Geschwind DH; Lah JJ; Levey AI, A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. *Cell Systems*, 2017 4(1): p. 60–+.
25. Musunuri S; Wetterhall M; Ingelsson M; Lannfelt L; Artemenko K; Bergquist J; Kulima K; Shevchenko G, Quantification of the Brain Proteome in Alzheimer's Disease Using Multiplexed Mass Spectrometry. *Journal of Proteome Research*, 2014 13(4): p. 2056–2068. [PubMed: 24606058]
26. Schonberger SJ; Edgar PF; Kydd R; Faull RLM; Cooper GJS, Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. *Proteomics*, 2001 1(12): p. 1519–1528. [PubMed: 11747211]
27. Ping LY; Duong DM; Yin LM; Gearing M; Lah JJ; Levey AI; Seyfried NT, Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease. *Scientific Data*, 2018 5.

28. Begcevic I; Kosanam H; Martinez-Morillo E; Dimitromanolakis A; Diamandis P; Kuzmanov U; Hazrati LN; Diamandis EP, Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. *Clinical Proteomics*, 2013 10.
29. Hondius DC; van Nierop P; Li KW; Hoozemans JJM; van der Schors RC; van Haastert ES; van der Vies SM; Rozemuller AJM; Smit AB, Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease. *Alzheimers & Dementia*, 2016 12(6): p. 654–668.
30. Edgar PF; Schonberger SJ; Dean B; Faull RLM; Kydd R; Cooper GJS, A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. *Molecular Psychiatry*, 1999 4(2): p. 173–178. [PubMed: 10208449]
31. Braak H; Braak E, Evolution of the neuropathology of Alzheimer's disease. *Acta neurologica Scandinavica. Supplementum*, 1996 165: p. 3–12. [PubMed: 8740983]
32. Cox J; Mann M, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nature Biotechnology*, 2008 26(12): p. 1367–1372.
33. Vizcaino JA; Csordas A; del-Toro N; Dienes JA; Griss J; Lavidas I; Mayer G; Perez-Riverol Y; Reisinger F; Ternent T; Xu QW; Wang R; Hermjakob H, 2016 update of the PRIDE database and its related tools (vol 44, pg D447, 2016). *Nucleic Acids Research*, 2016 44(22): p. 11033–11033. [PubMed: 27683222]
34. Spitzer M; Wildenhain J; Rappsilber J; Tyers M, BoxPlotR: a web tool for generation of box plots. *Nature Methods*, 2014 11(2): p. 121–122. [PubMed: 24481215]
35. Stefely JA; Kwiecien NW; Freiburger EC; Richards AL; Jochem A; Rush MJP; Ulbrich A; Robinson KP; Hutchins PD; Veling MT; Guo X; Kemmerer ZA; Connors KJ; Trujillo EA; Sokol J; Marx H; Westphall MS; Hebert AS; Pagliarini DJ; Coon JJ, Mitochondrial protein functions elucidated by multi-omic mass spectrometry profiling. *Nature Biotechnology*, 2016 34(11): p. 1191–+.
36. Hebert AS; Richards AL; Bailey DJ; Ulbrich A; Coughlin EE; Westphall MS; Coon JJ, The One Hour Yeast Proteome. *Molecular & Cellular Proteomics*, 2014 13(1): p. 339–347. [PubMed: 24143002]
37. Richards AL; Hebert AS; Ulbrich A; Bailey DJ; Coughlin EE; Westphall MS; Coon JJ, One-hour proteome analysis in yeast. *Nature Protocols*, 2015 10(5): p. 701–714. [PubMed: 25855955]
38. Beck M; Schmidt A; Malmstroem J; Claassen M; Ori A; Szymborska A; Herzog F; Rinner O; Ellenberg J; Aebersold R, The quantitative proteome of a human cell line. *Molecular Systems Biology*, 2011 7.
39. Nagaraj N; Wisniewski JR; Geiger T; Cox J; Kircher M; Kelso J; Paabo S; Mann M, Deep proteome and transcriptome mapping of a human cancer cell line. *Molecular Systems Biology*, 2011 7.
40. Sjostedt E; Fagerberg L; Hallstrom BM; Haggmark A; Mitsios N; Nilsson P; Ponten F; Hokfelt T; Uhlen M; Mulder J, Defining the Human Brain Proteome Using Transcriptomics and Antibody-Based Profiling with a Focus on the Cerebral Cortex. *Plos One*, 2015 10(6) : e0130028. 10.1371/journal.pone.0130028
41. Walloe S; Pakkenberg B; Fabricius K, Stereological estimation of total cell numbers in the human cerebral and cerebellar cortex. *Frontiers in Human Neuroscience*, 2014 8.
42. Niedzielska E; Smaga I; Gawlik M; Moniczewski A; Stankowicz P; Pera J; Filip M, Oxidative Stress in Neurodegenerative Diseases. *Molecular Neurobiology*, 2016 53(6): p. 4094–4125. [PubMed: 26198567]
43. Ramassamy C; Averill D; Beffert U; Bastianetto S; Theroux L; Lussier-Cacan S; Cohn JS; Christen Y; Davignon J; Quirion R; Poirier J, Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. *Free Radical Biology and Medicine*, 1999 27(5–6): p. 544–553. [PubMed: 10490274]
44. Swomley AM; Butterfield DA, Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics. *Archives of Toxicology*, 2015 89(10): p. 1669–1680. [PubMed: 26126631]
45. Venkateshappa C; Harish G; Mahadevan A; Bharath MMS; Shankar SK, Elevated Oxidative Stress and Decreased Antioxidant Function in the Human Hippocampus and Frontal Cortex with

- Increasing Age: Implications for Neurodegeneration in Alzheimer's Disease. *Neurochemical Research*, 2012 37(8): p. 1601–1614. [PubMed: 22461064]
46. Loring JF; Wen X; Lee JM; Seilhamer J; Somogyi R, A gene expression profile of Alzheimer's disease. *DNA and Cell Biology*, 2001 20(11): p. 683–695. [PubMed: 11788046]
 47. Andreev VP; Petyuk VA; Brewer HM; Karpievitch YV; Xie F; Clarke J; Camp D; Smith RD; Lieberman AP; Albin RL; Nawaz Z; El Hokayem J; Myers AJ, Label-Free Quantitative LC-MS Proteomics of Alzheimer's Disease and Normally Aged Human Brains. *Journal of Proteome Research*, 2012 11(6): p. 3053–3067. [PubMed: 22559202]
 48. Ajmo JM; Bailey LA; Howell MD; Cortez LK; Pennypacker KR; Mehta HN; Morgan D; Gordon MN; Gottschall PE, Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. *Journal of Neurochemistry*, 2010 113(3): p. 784–795. [PubMed: 20180882]
 49. Morawski M; Bruckner G; Jager C; Seeger G; Matthews RT; Arendt T, Involvement of Perineuronal and Perisynaptic Extracellular Matrix in Alzheimer's Disease Neuropathology. *Brain pathology*, 2012 22(4): p. 547–561. [PubMed: 22126211]
 50. Mufson EJ; Counts SE; Ginsberg SD, Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. *Neurochemical Research*, 2002 27(10): p. 1035–1048. [PubMed: 12462403]
 51. Olmos-Alonso A; Schettters STT; Sri S; Askew K; Mancuso R; Vargas-Caballero M; Holscher C; Perry VH; Gomez-Nicola D, Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. *Brain*, 2016 139: p. 891–907. [PubMed: 26747862]
 52. Dityatev A; Seidenbecher CI; Schachner M, Compartmentalization from the outside: the extracellular matrix and functional microdomains in the brain. *Trends in Neurosciences*, 2010 33(11): p. 503–512. [PubMed: 20832873]
 53. Huttenlocher PR; Dabholkar AS, Regional differences in synaptogenesis in human cerebral cortex. *Journal of Comparative Neurology*, 1997 387(2): p. 167–178. [PubMed: 9336221]
 54. Glavan G; Schliebs R; Zivin M, Synaptotagmins in Neurodegeneration. *Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology*, 2009 292(12): p. 1849–1862.
 55. Furube E; Kawai S; Inagaki H; Takagi S; Miyata S, Brain Region-dependent Heterogeneity and Dose-dependent Difference in Transient Microglia Population Increase during Lipopolysaccharide-induced Inflammation. *Scientific Reports*, 2018 8.
 56. Harada A; Oguchi K; Okabe S; Kuno J; Terada S; Ohshima T; Satoyoshitake R; Takei Y; Noda T; Hirokawa N, Altered Microtubule Organization in Small-Caliber Axons of Mice Lacking Tau-Protein. *Nature*, 1994 369(6480): p. 488–491. [PubMed: 8202139]
 57. Karch CM; Ezerskiy LA; Bertelsen S; Goate AM; Adgc, Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. *Plos One*, 2016 11(2): e0148717. 10.1371/journal.pone.0148717
 58. Hutter-Paier B; Huttunen HJ; Puglielli L; Eckman CB; Kim DY; Hofmeister A; Moir RD; Domnitz SB; Frosch MP; Windisch M; Kovacs DM, The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease (vol 44, pg 227, 2004). *Neuron*, 2010 68(5): p. 1014–1014.
 59. Le Corre S; Klafki HW; Plesnila N; Hubinger G; Obermeier A; Sahagun H; Monse B; Seneci P; Lewis J; Eriksen J; Zehr C; Yue M; McGowan E; Dickson DW; Hutton M; Roder HM, An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, 2006 103(25): p. 9673–9678. [PubMed: 16769887]
 60. Oldham MC; Horvath S; Geschwind DH, Conservation and evolution of gene coexpression networks in human and chimpanzee brains. *Proceedings of the National Academy of Sciences of the United States of America*, 2006 103(47): p. 17973–17978. [PubMed: 17101986]
 61. Cesaretti C; Spaccini L; Righini A; Parazzini C; Conte G; Crosti F; Redaelli S; Bulfamante G; Avagliano L; Rustico M, Prenatal Detection of 5q14.3 Duplication Including MEF2C and Brain Phenotype. *American Journal of Medical Genetics Part A*, 2016 170(5): p. 1352–1357.

62. Kempermann G; Chesler EJ; Lu L; Williams RW; Gage FH, Natural variation and genetic covariance in adult hippocampal neurogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, 2006 103(3): p. 780–785. [PubMed: 16407118]
63. Lee HJ; Lee K; Im H, alpha-Synuclein modulates neurite outgrowth by interacting with SPTBN1. *Biochemical and Biophysical Research Communications*, 2012 424(3): p. 497–502. [PubMed: 22771809]
64. Wisniewski JR; Hein MY; Cox J; Mann M, A “Proteomic Ruler” for Protein Copy Number and Concentration Estimation without Spike-in Standards. *Molecular & Cellular Proteomics*, 2014 13(12): p. 3497–3506. [PubMed: 25225357]
65. Rahman M; Previs SF; Kasumov T; Sadygov RG, Gaussian Process Modeling of Protein Turnover. *Journal of Proteome Research*, 2016 15(7): p. 2115–2122. [PubMed: 27229456]

Figure 1: Experimental Design

Gender, age and tangle severity is shown for each brain 0, +, ++ representing no tangles, intermediate tangle development, and severe tangles, respectively. The nine sections used in this experiment are displayed in the anatomical illustration below. The analysis workflow is pictured at the bottom including protein extraction, fractionation, mass spectrometry and data base searching.

Figure 2: Similarity among sections and individual brains.

(a) A total of 9735 proteins were identified overall with ~70% identified in all nine sections. (b) Heat map showing mean-normalized protein fold changes for all 6256 proteins with confident imputation (>50% of sections). C. Pairwise Pearson correlation between all samples of relative protein levels for confidently imputed proteins. Samples are labelled based on the sections three letter code followed by the tangle severity (0/+/++).

Figure 3: Differential Expression

(a) Plot comparing protein fold change in Middle Frontal Gyrus (MFG) region as compared to the Inferior Parietal Lobule (IPL) and Caudate Nucleus (CNC). Both correlations are strongly driven by small group of proteins with greater variation (>30%) and significance ($p < 0.05$) pictured in blue (b, c) Two clusters of differentially expressed proteins averaged by region and showing $\log_2$ fold changes. Numbers in parenthesis indicate proteins contained in that cluster. Larger clusters reflect the divergence of the cerebellum (CBM) while smaller clusters show expression contrast between inner and outer brain.

Figure 4: Region and Disease Specific Proteins

(a) Overlap of AD associated proteins from previous large-scale proteomic analyses and region-specific proteins from this study. (b) Overlap of significant proteins in expanded analysis. (c) Plot of significantly different protein abundances' fold change between disease and healthy tissue. Entorhinal cortex is on the x-axis and neocortex on the y-axis. Proteins are colored by variable they were found to be significant in. Points with black borders have 2-fold greater change with disease in one section over the other.

Figure 5: Tau Levels and Related Proteins

(a) The development of tau protein aggregates can be seen in tissue staining of both brains that contained tangles, with significantly denser, and more extensive aggregate formation in the severe individual (b) Elevated tau protein levels were observed relative to the tangle-free brain in many of the sections for both intermediate and severe tangle brains. NEO and ECX samples show average tau protein abundance in AD relative to healthy tissue from that same region. (c) Several proteins that clustered with tau proteins exhibited positively correlated expression profiles across the different samples (Pearson's $r > 0.50$). Many of these proteins are associated with healthy structural modification or have been implicated in the aggravation of the AD pathology.

Figure 6: Comparison to Young Brain Proteome

(a) Comparison between older samples analyzed here and “pooled adult” sample shows similar expression patterns between common sections sampled in the two experiments. Samples from previous analyses labelled as V1C: Visual Cortex, STR: Caudate Nucleus, MD: Thalamus, HIP: Hippocampus, DFC: Frontal Lobe, CBC: Cerebellum, AMY: Amygdala. (b) Proteins showing significantly different counts per cell. Proteins primarily increase with age, and the two most divergent sections are the Frontal Lobe and the Thalamus. (c) Diagram of proteins increasing with age shows very little overlap outside of group shared by both thalamus and frontal lobe.

Table 1:

Proteins identified in each sample with organized by both section and individual brain

Section	♀ 80 O	♂ 78 +	♀79++
Visual Cortex	7448	7138	7224
Entorhinal Cortex	7785	7680	7212
Amygdala	7647	7584	7041
Temporal Lobe	7839	7664	7337
Thalamus	7690	7281	7296
Caudate Nucleus	7408	6363	6753
Parietal Lobe	7811	7703	7341
Cerebellum	6953	-----	7088
Frontal Gyrus	7901	7602	7282